オプションチェーンは、Alumisの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Alumisの市場センチメントを評価します。.

Alumis (NASDAQ:ALMS) 株価情報, オプションチェーン

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

Alumis Inc

Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4368475-1&amp;h=1155357821&amp;u=https%3A%2F%2Foncology.labcorp.com%2Fplasma-complete&amp;a=Labcorp%C2%AE+Plasma+CompleteTM">Labcorp&#xAE; Plasma CompleteTM</a>, a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.

News

Laboratory Corporation Of America Holdings

Labcorp Launches Liquid Biopsy Test to Help Personalize Cancer Treatment

Keefe, Bruyette &amp; Woods analyst Bose George maintains Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) with a Market Perform and raises the price target from $205 to $230.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on Federal Agricultural, Raises Price Target to $230

WIIM

IOBT

IO Biotech shares are trading higher after the company announced preclinical results for a vaccine that targets TGF-β in tumors.

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $30 price target.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Buy and maintains $58 price target.

Reiteration

AGIO

HC Wainwright & Co. Reiterates Buy on Agios Pharmaceuticals, Maintains $58 Price Target

ARMK

Aramark Collegiate Hospitality Bags New Contract With Loyola Marymount University, To Manage Dining, Retail, Catering, And Concessions From May 2025

Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/ZM/earnings">closing bell, on Monday, Feb. 24, 2025.</a>
Analysts expect the San Jose, California-based company to report quarterly earnings at $1.35 per share, down from $1.42 per share in the year-ago period. Zoom projects quarterly revenue of $1.19 billion, compared to $1.15 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 25, Zoom reported third-quarter revenue of $1.18 billion, beating the consensus estimate of $1.16 billion. The communications company reported third-quarter adjusted earnings of $1.38 per share, beating analyst estimates of $1.31 per share.
Zoom shares fell 1.1% to close at $82.50 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Tyler Radke maintained a Neutral rating and cut the price target from $86 to $85 on Feb. 18, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Cantor Fitzgerald analyst Thomas Blakey initiated coverage on the stock with a Neutral rating and a price target of $87 on Jan. 16, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Wells Fargo analyst Michael Turrin upgraded the stock from Underweight to Equal-Weight rating and raised the price target from $70 to $85 on Jan. 7, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Morgan Stanley analyst Meta Marshall maintained an Equal-Weight rating and raised the price target from $86 to $96 on Dec. 18, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Rosenblatt analyst Catharine Trebnick maintained a Buy rating and raised the price target from $78 to $95 on Nov. 26, 2024. This analyst has an accuracy rate of 79%.</li>
</ul>
Considering buying ZM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23131658/image-184-1024x598.png" alt="" class="wp-image-794278" style="width:694px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23131658/image-184-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23131658/image-184-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23131658/image-184-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23131658/image-184.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp Zoom Communications Price Expectations Ahead Of Q4 Earnings

Vision Marine Technologies Inc. (the "Company," "Vision Marine," or "Vision Marine Technologies") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>), a company specializing in electric marine propulsion, announces the filing of a new patent application for the Outboard Power Control Unit (PCU) designed for Electric Marine Vessels.

Government

Regulations

VMAR

Vision Marine Files Patent for Outboard Power Control Unit for Electric Boats

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Great Lakes Dredge &amp; Dock Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>)</h3>
<ul>
<li>On Feb. 18, Great Lakes Dredge &amp; Dock posted weaker-than-expected quarterly sales. Lasse Petterson, President and Chief Executive Officer, said, &#8220;Great Lakes had an outstanding 2024, with strong project performance and exceptional financial results. We capped off the year with another strong quarter and ended 2024 with revenue of $762.7 million, net income of $57.3 million, and Adjusted EBITDA of $136.0 million, the latter two metrics being the second-highest in Great Lakes&#8217; history." The company's stock fell around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/GLDD">52-week low of $6.56</a>.</li>
<li>RSI Value: 24.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>GLDD Price Action: Shares of Great Lakes Dredge &amp; Dock fell 3.1% to close at $8.42 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">GLDD news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133749/image-186.png" alt="" class="wp-image-794301" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133749/image-186.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133749/image-186-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133749/image-186-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">FTI Consulting Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCN#NYSE">FCN</a>)&nbsp;</h3>
<ul>
<li>On Feb. 20, FTI Consulting reported worse-than-expected fourth-quarter financial results and issued FY25 guidance below estimates. Steven H. Gunby, President and Chief Executive Officer of FTI Consulting, commented, &#8220;Though a number of headwinds that we saw towards the end of 2024 resulted in second half performance that was below our expectations, we are pleased that, in aggregate, 2024 was yet another year of record revenues and earnings per share. Notwithstanding those headwinds, many of which we expect to persist into 2025, we continue to feel confident in the powerful multiyear growth trajectory that we are on.&#8221; The company's stock fell around 14% over the past five days and <a href="https://www.benzinga.com/quote/FCN">has a 52-week low</a> of $161.24.</li>
<li>RSI Value: 22.2</li>
<li>FCN Price Action: Shares of FTI Consulting gained 1% to close at $164.69 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">FCN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133828/image-187.png" alt="" class="wp-image-794302" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133828/image-187.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133828/image-187-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23133828/image-187-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

Long Ideas

Pre-Market Outlook

GLDD

Top 2 Industrials Stocks That Are Set To Fly This Quarter

Connexa Sports Technologies Inc. - Common Stock

YYAI

Connexa Sports Technologies shares are trading higher after the company announced it signed a multi-channel-network (MCN) deal to create content for TikTok in the MENA region.

Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/TCOM/earnings">closing bell on Monday, Feb. 24.</a>
Analysts expect the Singapore-based company to report quarterly earnings at $3.95 per share, down from $4.00 per share in the year-ago period. Trip.com projects quarterly revenue of $12.32 billion, compared to $10.32 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 11, Trip.com disclosed that Mr. Junjie He, a director nominated by Baidu, tendered his resignation as a director of the Company, and that Mr. Rong Luo, the executive vice president of Baidu Inc., has been appointed as a successor director of Trip.com Group.
Trip.com shares gained 1.4% to close at $67.02 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/tcom/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Benchmark analyst Fawne Jiang reiterated a Buy rating with a price target of $80 on Jan. 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Brian Gong maintained a Buy rating and raised the price target from $73 to $78 on Jan. 3, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Barclays analyst Jiong Shao maintained an Overweight rating and boosted the price target from $76 to $84 on Nov. 20, 2024. This analyst has an accuracy rate of 69%.</li>
<li>TD Cowen analyst Kevin Kopelman maintained a Buy rating and raised the price target from $56 to $71 on Nov. 19, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Mizuho analyst James Lee maintained an Outperform rating and boosted the price target from $65 to $78 on Nov. 12, 2024. This analyst has an accuracy rate of 80%.</li>
</ul>
Considering buying TCOM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23132731/image-185-1024x612.png" alt="" class="wp-image-794293" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23132731/image-185-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23132731/image-185-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23132731/image-185-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23132731/image-185.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

TCOM

Trip.com Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Kaiser Aluminum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>)</h3>
<ul>
<li>Dividend Yield: 4.29%</li>
<li>Benchmark analyst Josh Sullivan maintained a Buy rating and raised the price target from $84 to $100 on July 12, 2024. This analyst has an accuracy rate of 86%.</li>
<li>UBS analyst Curt Woodworth initiated coverage on the stock with a Neutral rating and a price target of $67 on Jan. 16, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Feb. 18, Kaiser Aluminum posted downbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">KALU news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140333/image-188.png" alt="" class="wp-image-794311" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140333/image-188.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140333/image-188-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140333/image-188-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Sonoco Products Company &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>)</h3>
<ul>
<li>Dividend Yield: 4.44%</li>
<li>Citigroup analyst Anthony Pettinari maintained a Buy rating and cut the price target from $59 to $55 on Jan. 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Wells Fargo analyst Gabe Hajde maintained an Underweight rating and cut the price target from $52 to $50 on Jan. 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On Feb. 18, Sonoco Products missed fourth-quarter EPS and revenue estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest SON <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140414/image-189.png" alt="" class="wp-image-794312" style="width:691px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140414/image-189.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140414/image-189-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140414/image-189-768x694.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>)</h3>
<ul>
<li>Dividend Yield: 4.37%</li>
<li>Wells Fargo analyst Chris Carey maintained an Overweight rating and cut the price target from $85 to $80 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and slashed the price target from $85 to $80 on Nov. 7, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Jan. 29, the company reported a first-quarter adjusted loss per share of 89 cents, which is narrower than the street view of a $1.23 loss.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest SMG <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="895" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140459/image-190.png" alt="" class="wp-image-794315" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140459/image-190.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140459/image-190-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/23140459/image-190-768x710.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

Dividends

KALU

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields

Rosenblatt analyst Hans Mosesmann maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and maintains $220 price target.

NVDA

Rosenblatt Maintains Buy on NVIDIA, Maintains $220 Price Target

Keefe, Bruyette &amp; Woods analyst Bose George upgrades NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) from Market Perform to Outperform and maintains the price target from $43 to $43.

Upgrades

NMIH

Keefe, Bruyette & Woods Upgrades NMI Holdings to Outperform, Maintains Price Target to $43

Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>), a leader in space infrastructure for the next generation space economy, announced today that its flight-proven Sentinel camera technology (SentinelCam) will launch on board Athena, Intuitive Machines' Nova-C lunar lander, on IM-2, the company's second mission to the Moon. Redwire delivered Terrain Relative Navigation and Hazard Detection and Avoidance cameras from its Sentinel product line. These cameras are part of a suite of technologies supporting the lander's navigation and landing.

LUNR

Redwire's SentinelCam to Support Intuitive Machines' Second Moon Mission

IVVD

Invivyd shares are trading lower after the company announced the FDA has declined its request to expand its existing emergency use authorization of PEMGARDA.

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $64 price target.

RYTM

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target

As of Feb. 24, 2025, three stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Kingsoft Cloud Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)</h3>
<ul>
<li>On Nov. 19, 2024, Kingsoft Cloud reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million. The company's stock gained around 117% over the past month and has a <a href="https://www.benzinga.com/quote/KC">52-week high of $22.26</a>.</li>
<li>RSI Value: 70.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KC Price Action: Shares of Kingsoft Cloud gained 2.5% to close at $20.67 on Friday.</li>
</ul>
<h3 class="wp-block-heading">VNET Group Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)</h3>
<ul>
<li>On Nov. 20, VNET Group reported third-quarter EPS and revenue that rose year-over-year. &#8220;We achieved strong third quarter results mainly driven by our wholesale IDC business,&#8221; said Josh Sheng Chen, Founder, Executive Chairperson and interim Chief Executive Officer of VNET. The company's stock gained around 113% over the past month and <a href="https://www.benzinga.com/quote/VNET">has a 52-week high</a> of $16.13.</li>
<li>RSI Value: 89</li>
<li>VNET Price Action: Shares of VNET Group fell 0.6% to close at $14.59 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)</h3>
<ul>
<li>On Feb. 21, Pony AI launched paid robotaxi services connecting Guangzhou's city center with Baiyun International Airport and South Railway Station. The company said it is the first and only approved to operate on these high-demand routes. The company's stock gained around 77% over the past month and has a <a href="https://www.benzinga.com/quote/PONY">52-week high</a> of $23.88.</li>
<li>RSI Value: 79.8</li>
<li>PONY Price Action: Shares of Pony AI gained 32.1% to close at $23.61 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>

Short Ideas

PONY

VNET

Top 3 Tech Stocks That May Crash In Q1

ATCH

AtlasClear shares are trading higher. The company reported Q2 financial results.

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) ("HUSA" or the "Company") today announced that it has entered into a definitive agreement to acquire Abundia Global Impact Group, LLC ("AGIG"), a company specializing in converting waste into high value fuels and chemicals. The acquisition supports HUSA's strategy to diversify its portfolio, expand its global footprint and execute its comprehensive strategy aimed at driving shareholder value through innovation in the renewable energy sector. The agreement is subject to HUSA shareholder approval and standard closing conditions.
Under the terms of the agreement, HUSA will acquire 100% of AGIG's issued and outstanding units from AGIG's members and HUSA will issue to AGIG's members a number of shares of HUSA common stock which shall equal 94% of HUSA's aggregate issued and outstanding common stock at the time of the Closing. AGIG is preparing to build its first advanced plastic recycling facility in Cedar Port, Texas. The facility represents the first phase of a structured, capital-efficient growth plan aimed at scaling and deploying AGIG's suite of technologies for producing renewable fuels and chemicals from waste.

HUSA

Houston American Energy to Acquire Abundia Global, Expands Into Renewable Fuels

Press Releases

Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Management

Alumis Strengthens Leadership Team with Key Appointments

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Comments

Alumis

Alumis (ALMS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル